CNS Drugs

, Volume 19, Issue 7, pp 597–622 | Cite as

Place of Drug Therapy in the Treatment of Carotid Stenosis

Review Article


Carotid stenosis is an important cause of transient ischaemic attacks and stroke. The cause of carotid stenosis is most often atherosclerosis; contributing to the pathogenesis of the lesion are endothelial injury, inflammation, lipid deposition, plaque formation, fibrin, platelets and thrombin. Carotid stenosis accounts for 10–20% of cases of brain infarction, depending on the population studied. Despite successful treatment of selected patients who have had an acute ischaemic stroke with tissue plasminogen activator and the promise of other experimental therapies, prevention remains the best approach to reducing the impact of ischaemic stroke. High-risk or stroke-prone patients can be identified and targeted for specific interventions

At this juncture, treatment of carotid stenosis is a well established therapeutic target and a pillar of stroke prevention. There are two main strategies for the treatment of carotid stenosis. The first approach is to stabilise or halt the progression of the carotid plaque through risk factor modification and medication. Hypertension, diabetes mellitus, smoking, obesity and high cholesterol levels are closely associated with carotid stenosis and stroke; control of these factors may decrease the risk of plaque formation and progression. The second approach is to eliminate or reduce carotid stenosis through carotid endarterectomy or carotid angioplasty and stenting. Carotid endarterectomy, which is the mainstay of therapy for severe carotid stenosis, is beyond the scope of this review

Anticoagulants seem to play little role (if any) in the medical (i.e. non-surgical)treatment of carotid stenosis. Adoption of a healthy lifestyle combined with the reduction of risk factors has been shown to lead to a reduction in the extent of carotid stenosis. The medical treatment of carotid stenosis should be based on the triad of the reduction of risk factors, patient education, and use of antiplatelet agents


  1. 1.
    Dogan A, Dempsey RJ. Diagnostic modalities for carotid artery disease. Neurosurg Clin N Am 2000 Apr; 11(2): 205–20PubMedGoogle Scholar
  2. 2.
    American Stroke Association [online]. Available from URL: [Accessed 2002 Aug 8]
  3. 3.
    American Stroke Association [online]. Available from URL: [Accessed 2002 Aug 8]
  4. 4.
    Sacco RL. Clinical practice: extracranial carotid stenosis. N Engl J Med 2001 Oct 11; 345(15): 1113–8PubMedCrossRefGoogle Scholar
  5. 5.
    Fisher CM, Gore I, Okabe N, et al. Atherosclerosis of the carotid and vertebral arteries-extracranial and intracranial. J Neuropathol Exp Neurol 1965; 24: 455–76CrossRefGoogle Scholar
  6. 6.
    Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the stroke council of the American Heart Association. Stroke 2001; 32: 280–99PubMedCrossRefGoogle Scholar
  7. 7.
    Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002; 106: 388–91PubMedCrossRefGoogle Scholar
  8. 8.
    Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis: North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998 Nov 12; 339(20): 1415–2PubMedCrossRefGoogle Scholar
  9. 9.
    Endarterectomy for asymptomatic carotid artery stenosis: Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995 May 10; 273(18): 1421–8CrossRefGoogle Scholar
  10. 10.
    European Carotid Surgery Trialists’ Group. Randomized trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379–87CrossRefGoogle Scholar
  11. 11.
    Paciaroni M, Eliasziw M, Sharpe BL, et al. Long-term clinical and angiographic outcomes in symptomatic patients with 70% to 99% carotid artery stenosis. Stroke 2000 Sep; 31(9): 2037–42PubMedCrossRefGoogle Scholar
  12. 12.
    Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internal carotid artery stenosis. N Engl J Med 2000 Jun 8; 342(23): 1693–700PubMedCrossRefGoogle Scholar
  13. 13.
    Rothwell PM, Gutnikov SA, Warlow CP. For the European Carotid Surgery Trialists’ Collaboration. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke 2003 Feb; 34(2): 514–23Google Scholar
  14. 14.
    Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995 Mar; 25(3): 305–13PubMedCrossRefGoogle Scholar
  15. 15.
    The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157(21): 2413–46CrossRefGoogle Scholar
  16. 16.
    Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999 Mar 24–31; 281(12): 1112–20PubMedCrossRefGoogle Scholar
  17. 17.
    Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335(8693): 827–38PubMedCrossRefGoogle Scholar
  18. 18.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991 Jun 26; 265(24): 3255–64CrossRefGoogle Scholar
  19. 19.
    Burt VL, Culter JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995 Jul; 26(1): 60–9PubMedCrossRefGoogle Scholar
  20. 20.
    Klungel OH, Strieker BH, Paes AH, et al. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke 1999 Jul; 30(7): 1312–8PubMedCrossRefGoogle Scholar
  21. 21.
    Friday GH. Antihypertensive medication compliance in African-American stroke patients: behavioral epidemiology and interventions. Neuroepidemiology 1999; 18(5): 223–30PubMedCrossRefGoogle Scholar
  22. 22.
    Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002 Feb; 33(2): 572–7PubMedCrossRefGoogle Scholar
  23. 23.
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. [Published erratum appears in N Engl J Med 2000 Mar 9; 342 (10): 748]. N Engl J Med 2000 Jan 20; 342(3): 145–53Google Scholar
  24. 24.
    Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001 Feb 20; 103(7): 919–25PubMedCrossRefGoogle Scholar
  25. 25.
    PROGRESS Collaborative Group Members. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep 29; 358(9287): 1033–41CrossRefGoogle Scholar
  26. 26.
    Kool MJ, Hoeks AP, Struijker Boudier HA, et al. Short- and long-term effects of smoking on arterial wall properties in habitual smokers. J Am Coll Cardiol 1993 Dec; 22(7): 1881–6PubMedCrossRefGoogle Scholar
  27. 27.
    Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998 Jan 14; 279(2): 119–24PubMedCrossRefGoogle Scholar
  28. 28.
    O’Leary DH, Polak JF, Kronmal RA, et al. Distribution andcorrelates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke 1992 Dec; 23(12): 1752–60PubMedCrossRefGoogle Scholar
  29. 29.
    Sacco RL, Roberts JK, Boden-Albala B, et al. The Northern Manhattan Stroke Study. Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population. Stroke 1997 May; 28(5): 929–35Google Scholar
  30. 30.
    Mast H, Thompson JL, Lin IF, et al. Cigarette smoking as a determinant of high-grade carotid artery stenosis in Hispanic, black, and white patients with stroke or transient ischemic attack. Stroke 1998 May; 29(5): 908–12PubMedCrossRefGoogle Scholar
  31. 31.
    Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991 Aug 1; 134(3): 250–6PubMedGoogle Scholar
  32. 32.
    Wolf PA. Cigarettes, alcohol, and stroke. N Engl J Med 1986 Oct 23; 315(17): 1087–9PubMedCrossRefGoogle Scholar
  33. 33.
    Cruickshank JM, Neil-Dwyer G, Dorrance DE, et al. Acute effects of smoking on blood pressure and cerebral blood flow. J Hum Hypertens 1989; 3: 443–9PubMedGoogle Scholar
  34. 34.
    Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989 Mar 25; 298(6676): 789–94PubMedCrossRefGoogle Scholar
  35. 35.
    National Center for Health Statistics. Healthy people 2000 review, 1989–1999. Hyattsville (MD): US Dept of Health and Human Services, 1999Google Scholar
  36. 36.
    West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000 Dec; 55: 987–99Google Scholar
  37. 37.
    Raw M, Anderson P, Batra A, et al. World Health Organization European Partnership Project to Reduce Tobacco Dependence. WHO Europe evidence based recommendations on the treatment of tobacco dependence. Tob Control 2002; 11: 44–6Google Scholar
  38. 38.
    Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals: a guide to effective smoking cessation interventions for the health care system. Health Education Authority. Thorax 1998; 53(Pt 1 Suppl. 5): S1–19CrossRefGoogle Scholar
  39. 39.
    Bier ID, Wilson J, Studt P, et al. Auricular acupuncture, education, and smoking cessation: a randomized, sham-controlled trial. Am J Public Health 2002; 92: 1642–7PubMedCrossRefGoogle Scholar
  40. 40.
    White AR, Resch KL, Ernst E. A meta-analysis of acupuncture techniques for smoking cessation. Tob Control 1999; 8: 393–397PubMedCrossRefGoogle Scholar
  41. 41.
    Fiore MC, Bailey WC, Cohen SJ, et al. Smoking cessation: clinical practice guideline No 18. Rockville (MD): US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996 AprGoogle Scholar
  42. 42.
    Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guideline. Rockville (MD): US Department of Health and Human Services. Public Health Service, 2000 JunGoogle Scholar
  43. 43.
    Wolf PA, D’Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham study. Stroke 1991 Mar; 22(3): 312–8PubMedCrossRefGoogle Scholar
  44. 44.
    Kuller LH, Dorman JS, Wolf PA. Cerebrovascular diseases and diabetes. In: National Diabetes Data Group Department of Health and Human Services, National Institutes of Health, editor. Diabetes in America: diabetes data compiled for 1984. Bethesda (MD): National Institutes of Health, 1985: 1–18Google Scholar
  45. 45.
    Karem JH. Diabetes mellitus. In: Tierney LH, McPhee SJ, Papdakis MA, editors. Current medical diagnosis & treatment. Stamford (CT): Appleton & Lange, 1996Google Scholar
  46. 46.
    Kännel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979 May 11; 241(19): 2035–8PubMedCrossRefGoogle Scholar
  47. 47.
    Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial (MRFIT). Diabetes Care 1993 Feb; 16(2): 434–44PubMedCrossRefGoogle Scholar
  48. 48.
    Bell DS. Stroke in the diabetic patient. Diabetes Care 1994 Mar; 17(3): 213–9PubMedCrossRefGoogle Scholar
  49. 49.
    Folsom AR, Eckfeldt JH, Weitzman S, et al. Relation of carotid artery wall thickness in diabetes mellitus, fasting glucose and insulin, body size, and physical activity: Atherosclerosis Risk in Communities Study Investigators. Stroke 1994 Jan; 25(1): 66–73PubMedCrossRefGoogle Scholar
  50. 50.
    Kuller LH, National Diabetes Data Group. Stroke and diabetes. In: National Diabetes Data Group, editors. Diabetes in America. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995: 449–56Google Scholar
  51. 51.
    Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999 Sep 7; 100(10): 1134–46PubMedCrossRefGoogle Scholar
  52. 52.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 Sep 12; 317(7160): 703–13CrossRefGoogle Scholar
  53. 53.
    Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996 Dec 18; 276(23): 1886–92PubMedCrossRefGoogle Scholar
  54. 54.
    UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 Sep 12; 352(9131): 854–65CrossRefGoogle Scholar
  55. 55.
    Tuomilehto J, Rastenyte D. Diabetes and glucose intolerance as risk factors for stroke. J Cardiovasc Risk 1999 Aug; 6(4): 241–9PubMedGoogle Scholar
  56. 56.
    Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995 Dec; 38(6): 869–80CrossRefGoogle Scholar
  57. 57.
    Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis 1978 Apr; 31(4): 201–306CrossRefGoogle Scholar
  58. 58.
    Oliver MF. Cholesterol and strokes: cholesterol lowering is indicated for strokes due to carotid atheroma. BMJ 2000 Feb 19; 320(7233): 459–60PubMedCrossRefGoogle Scholar
  59. 59.
    Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995 Dec 23–30; 346(8991–8992): 1647–53Google Scholar
  60. 60.
    Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003; 34: 623–31PubMedCrossRefGoogle Scholar
  61. 61.
    Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation 1996; 94: 273–8PubMedCrossRefGoogle Scholar
  62. 62.
    Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955–61PubMedCrossRefGoogle Scholar
  63. 63.
    Reardon MF, Nestel PJ, Craig IH, et al. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 1985; 71: 881–8PubMedCrossRefGoogle Scholar
  64. 64.
    Rosseneu M, Fruchart JC, Bard JM, et al. Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects: the EARS Study. Circulation 1994; 89: 1967–73PubMedCrossRefGoogle Scholar
  65. 65.
    Jeng JS, Sacco RL, Kargman DE, et al. Apolipoproteins and carotid artery atherosclerosis in an elderly multiethnic population: the Northern Manhattan stroke study. Atherosclerosis 2002; 165: 317–25PubMedCrossRefGoogle Scholar
  66. 66.
    Steering Committee of the Physicians’ Health Study Research Group: Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35CrossRefGoogle Scholar
  67. 67.
    Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481–5PubMedCrossRefGoogle Scholar
  68. 68.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344(8934): 1383–9Google Scholar
  69. 69.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996 Oct 3; 335(14): 1001–9PubMedCrossRefGoogle Scholar
  70. 70.
    LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998 Nov 5; 339(19): 1349–57CrossRefGoogle Scholar
  71. 71.
    Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995 Nov 1; 92(9): 2419–25PubMedCrossRefGoogle Scholar
  72. 72.
    Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997 Jul 23–30; 278(4): 313–21PubMedCrossRefGoogle Scholar
  73. 73.
    Blauw GJ, Lagaay AM, Smelt AH, et al. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-Co-A reductase inhibitors. Stroke 1997 May; 28(5): 946–50PubMedCrossRefGoogle Scholar
  74. 74.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 Nov 16; 333(20): 1301–7PubMedCrossRefGoogle Scholar
  75. 75.
    Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999 Jan 19; 99(2): 216–23PubMedCrossRefGoogle Scholar
  76. 76.
    Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999 Feb; 19(2): 187–95PubMedCrossRefGoogle Scholar
  77. 77.
    Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993 Jul; 88(1): 20–888PubMedCrossRefGoogle Scholar
  78. 78.
    O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and strokes in older adults. N Engl J Med 1999 Jan 7; 340(1): 14–22PubMedCrossRefGoogle Scholar
  79. 79.
    Mack WJ, Selzer RH, Hodis HN, et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993 Dec; 24(12): 1779–83PubMedCrossRefGoogle Scholar
  80. 80.
    Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994 Oct; 90(4): 1679–87PubMedCrossRefGoogle Scholar
  81. 81.
    Bjelajac A, Goo AK, Weart CW. Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors. Ann Pharmacother 1996 Nov; 30(11): 1304–15PubMedGoogle Scholar
  82. 82.
    MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Circulation 1998 May 12; 97(18): 1784–90PubMedCrossRefGoogle Scholar
  83. 83.
    Crouse Jr III, Byington RP, Bond MA, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). [Published erratum appears in Am J Cardiol 1995 Apr 15; 75 (12): 862]. Am J Cardiol 1995 Mar 1; 75(7): 455–9PubMedCrossRefGoogle Scholar
  84. 84.
    Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157(21): 2413–46CrossRefGoogle Scholar
  85. 85.
    Furberg CD. Natural statins and stroke risk. Circulation 1999 Jan 19; 99(2): 185–8PubMedCrossRefGoogle Scholar
  86. 86.
    Karason K, Wikstrand J, Sjostrom L, et al. Weight loss and progression of early atherosclerosis in the carotid artery: a four year controlled study of obese subjects. Int J Obes Relat Metab Disord 1999 Sep; 23(9): 948–56PubMedCrossRefGoogle Scholar
  87. 87.
    Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998 Apr 9; 338(15): 1042–50PubMedCrossRefGoogle Scholar
  88. 88.
    Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995 Oct 4; 274(13): 1049–57PubMedCrossRefGoogle Scholar
  89. 89.
    Homocysteine Lowering Trialists’ Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998 Mar 21; 316(7135): 894–8CrossRefGoogle Scholar
  90. 90.
    van den Berg M, Franken DG, Boers GH, et al. Combined vitamin B6 plus folic acid in young patients with arteriosclerosis and hyperhomocysteinaemia. J Vasc Surg 1994 Dec; 20(6): 933–40PubMedCrossRefGoogle Scholar
  91. 91.
    Hercberg S, Galan P, Preziosi P, et al. Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. Supplementation en Vitamines et Mineraux AntioXydants Study. Int J Vitam Nutr Res 1998; 68: 3–20Google Scholar
  92. 92.
    Manson JE, Gaziano JM, Jonas MA, et al. Antioxidants and cardiovascular disease: a review. J Am Coll Nutr 1993; 12: 426–32PubMedGoogle Scholar
  93. 93.
    Hennekens CH, Gaziano JM, Manson JE, et al. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Am J Clin Nutr 1995; 62(6 Suppl.): 1777S–380SGoogle Scholar
  94. 94.
    Delanty N, Dichter MA. Oxidative injury in the nervous system. Acta Neurol Scand 1998; 98: 145–53PubMedCrossRefGoogle Scholar
  95. 95.
    Vatassery GT, Bauer T, Dysken M. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. Am J Clin Nutr 1999; 70: 793–801PubMedGoogle Scholar
  96. 96.
    Todd S, Woodward M, Tunstall-Pedoe H, et al. Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes mortality: results from the Scottish Heart Health Study. Am J Epidemiol 1999; 150: 1073–80PubMedCrossRefGoogle Scholar
  97. 97.
    Ascherio A, Rimm EB, Hernan MA, et al. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Ann Intern Med 1999; 130: 963–70PubMedGoogle Scholar
  98. 98.
    Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 1995; 62(6 Suppl.): 1381S–4SPubMedGoogle Scholar
  99. 99.
    Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781–6PubMedCrossRefGoogle Scholar
  100. 100.
    Kohlmeier L, Hastings SB. Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention. Am J Clin Nutr 1995; 62(6 Suppl.): 1370S–6SPubMedGoogle Scholar
  101. 101.
    Stampfer MJ, Rimm EB. Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Am J Clin Nutr 1995; 62(6 Suppl.): 1365S–9SPubMedGoogle Scholar
  102. 102.
    Diaz MN, Frei B, Vita JA, et al. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408–16PubMedCrossRefGoogle Scholar
  103. 103.
    Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease: European COMAC Group. Circulation 1998; 97: 437–43PubMedCrossRefGoogle Scholar
  104. 104.
    Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke 2000 Nov; 31: 2751–66PubMedCrossRefGoogle Scholar
  105. 105.
    Jacques PR, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999 May 13; 340: 1449–54PubMedCrossRefGoogle Scholar
  106. 106.
    Eikelboom JW, Lonn E, Genest J, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999 Sep 7; 131: 363–75PubMedGoogle Scholar
  107. 107.
    Salonen JT, Salonen R, Seppänen K, et al. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ 1991 Mar 30; 302: 756–60PubMedCrossRefGoogle Scholar
  108. 108.
    Nyyssonen K, Parviainen MT, Salonen R, et al. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997 Mar 1; 314: 634–8PubMedCrossRefGoogle Scholar
  109. 109.
    Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000 Nov; 248: 377–86PubMedCrossRefGoogle Scholar
  110. 110.
    Yokoyama T, Date C, Kokubo Y, et al. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community: the Shibata study. Stroke 2000 Oct; 31: 2287–94PubMedCrossRefGoogle Scholar
  111. 111.
    Gey KF, Stahelin HB, Eichholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke: Basel Prospective Study. Clin Investig 1993 Jan; 71: 3–6PubMedCrossRefGoogle Scholar
  112. 112.
    Gale CR, Martyn CN, Winter PD, et al. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ 1995 Jun 17; 310: 1563–6PubMedCrossRefGoogle Scholar
  113. 113.
    Kurl S, Tuomainen TP, Laukkanen JA, et al. Plasma vitamin C modifies the association between hypertension and risk of stroke. Stroke 2002 Jun; 33: 1568–73PubMedCrossRefGoogle Scholar
  114. 114.
    Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989 Apr 6; 320: 915–24PubMedCrossRefGoogle Scholar
  115. 115.
    Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994 Sep 17; 344: 793–5PubMedCrossRefGoogle Scholar
  116. 116.
    Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1987 Nov; 84: 7725–9PubMedCrossRefGoogle Scholar
  117. 117.
    Verlangieri AJ, Bush MJ. Effects of alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. J Am Coll Nutr 1992; 11: 131–8PubMedGoogle Scholar
  118. 118.
    Williams RJ, Motteram JM, Sharp CH, et al. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992 Apr; 94: 153–9PubMedCrossRefGoogle Scholar
  119. 119.
    Knekt P, Reunanen A, Jarvinen R, et al. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994 Jun 15; 139: 1180–9PubMedGoogle Scholar
  120. 120.
    Gaziano JM, Manson JE, Branch LG, et al. A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol 1995 Jul; 5: 255–60PubMedCrossRefGoogle Scholar
  121. 121.
    Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996 May 2; 334: 1156–62PubMedCrossRefGoogle Scholar
  122. 122.
    Klipstein-Grobusch K, Geleijnse JM, den Breeijen JH, et al. Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999 Feb; 69: 261–6PubMedGoogle Scholar
  123. 123.
    Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993 May 20; 328: 1444–9PubMedCrossRefGoogle Scholar
  124. 124.
    Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993 May 20; 328: 1450–6PubMedCrossRefGoogle Scholar
  125. 125.
    Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995 Jun 21; 273: 1849–54PubMedCrossRefGoogle Scholar
  126. 126.
    Rapola JM, Virtamo J, Haukka JK, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. [Published erratum appears in JAMA 1998; 279: 1528]. JAMA 1996 Mar 6; 275(9): 693–8PubMedCrossRefGoogle Scholar
  127. 127.
    Jialal I, Devaraj S, Huet BA, et al. GISSI-Prevenzione trial. Lancet 1999 Oct 30; 354: 1554PubMedCrossRefGoogle Scholar
  128. 128.
    The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154–60CrossRefGoogle Scholar
  129. 129.
    Jialal I, Devaraj S. Vitamin E supplementation and cardiovascular events in high-risk patients [letter]. N Engl J Med 2000; 342(25): 1917PubMedCrossRefGoogle Scholar
  130. 130.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jun 6; 360: 23–33CrossRefGoogle Scholar
  131. 131.
    Gill JS, Zezulka AV, Shipley MJ, et al. Stroke and alcohol consumption. N Engl J Med 1986 Oct 23; 315(17): 1041–6PubMedCrossRefGoogle Scholar
  132. 132.
    Thornton J, Symes C, Heaton K. Moderate alcohol intake reduces bile cholesterol saturation and raises HDL cholesterol. Lancet 1983 Oct 8; 2(8354): 819–22PubMedCrossRefGoogle Scholar
  133. 133.
    Pellegrini N, Pareti FI, Stabile F, et al. Effects of moderate consumption of red wine on platelet aggregation and haemostatic variables in healthy volunteers. Eur J Clin Nutr 1996 Apr; 50(4): 209–13PubMedGoogle Scholar
  134. 134.
    US Preventive Services Task Force. Guide to clinical preventive services: report of the US Preventive Services Task Force. 2nd ed. Baltimore (MD): Williams & Wilkins, 1996Google Scholar
  135. 135.
    Kokkinos PF, Narayan P, Colleran JA, et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med Nov 30; 333 (22): 1462-7Google Scholar
  136. 136.
    Blair SN, Kampert JB, Kohl III HW, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996 Jul 17; 276(3): 205–10PubMedCrossRefGoogle Scholar
  137. 137.
    Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991 Sep 28; 338(8770): 774–8PubMedCrossRefGoogle Scholar
  138. 138.
    Lakka TA, Salonen JT. Moderate to high intensity conditioning leisure time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men. J Clin Epidemiol 1993 Oct; 46(10): 1119–27PubMedCrossRefGoogle Scholar
  139. 139.
    Wang JS, Jen CJ, Chen HI. Effects of exercise training and deconditioning on platelet function in men. Arterioscler Thromb Vasc Biol 1995 Oct; 15(10): 1668–74PubMedCrossRefGoogle Scholar
  140. 140.
    Rangemark C, Hedner JA, Carlson JT, et al. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995 Apr; 18(3): 188–94PubMedGoogle Scholar
  141. 141.
    Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996 May 16; 334(20): 1298–303PubMedCrossRefGoogle Scholar
  142. 142.
    Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999 Jul 23; 85(2): 199–207PubMedCrossRefGoogle Scholar
  143. 143.
    DeGraba TJ, Siren AL, Penix L, et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 1998 Jul; 29(7): 1405–10PubMedCrossRefGoogle Scholar
  144. 144.
    Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999 Jul; 145(1): 33–43PubMedCrossRefGoogle Scholar
  145. 145.
    Jander S, Sitzer M, Schumann R, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke 1998 Aug; 29(8): 1625–30PubMedCrossRefGoogle Scholar
  146. 146.
    Esposito G, Blasi F, Allegra L, et al. Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. Ann Vasc Surg 1999 Jul; 13(4): 421–5PubMedCrossRefGoogle Scholar
  147. 147.
    Chiu B. Multiple infections in carotid atherosclerotic plaques. Am Heart J 1999 Nov; 138 (5 Pt 2): S534–6PubMedCrossRefGoogle Scholar
  148. 148.
    Maass M, Krause E, Engel PM, et al. Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology 1997 Aug; 48(8): 699–706PubMedCrossRefGoogle Scholar
  149. 149.
    Yamashita K, Ouchi K, Shirai M, et al. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 1998 Apr; 29(4): 773–8PubMedCrossRefGoogle Scholar
  150. 150.
    Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995 Dec 15; 92(12): 3397–400PubMedCrossRefGoogle Scholar
  151. 151.
    Markus HS, Sitzer M, Carrington D, et al. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 1999 Aug 24; 100(8): 832–7PubMedCrossRefGoogle Scholar
  152. 152.
    Fagerberg B, Gnarpe J, Gnarpe H, et al. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999 Feb; 30(2): 299–305PubMedCrossRefGoogle Scholar
  153. 153.
    Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med 1993 Nov; 95(5): 499–504PubMedCrossRefGoogle Scholar
  154. 154.
    Cook PJ, Honeybourne D, Lip GY, et al. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke 1998 Feb; 29(2): 404–10PubMedCrossRefGoogle Scholar
  155. 155.
    Wimmer ML, Sandmann-Strupp R, Saikku P, et al. Association of chlamydial infection with cerebrovascular disease. Stroke 1996 Dec; 27(12): 2207–10PubMedCrossRefGoogle Scholar
  156. 156.
    Melissano G, Blasi F, Esposito G, et al. Chlamydia pneumoniae eradication from carotid plaques: results of an open, randomised treatment study. Eur J Vasc Endovasc Surg 1999 Oct; 18(4): 355–9PubMedCrossRefGoogle Scholar
  157. 157.
    Ridker PM, Hennekens CH, Stampfer MJ, et al. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998 Dec 22–29; 98(25): 2796–9PubMedCrossRefGoogle Scholar
  158. 158.
    Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997 Apr 3; 336(14): 973–9PubMedCrossRefGoogle Scholar
  159. 159.
    Feng D, Tracy RP, Lipinska I, et al. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 2000 Jan; 9(1): 37–41PubMedCrossRefGoogle Scholar
  160. 160.
    Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol And Recurrent Events (CARE) Investigators. Circulation 1998 Sep 1; 98(9): 839–44PubMedCrossRefGoogle Scholar
  161. 161.
    Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol And Recurrent Events (CARE) Investigators. Circulation 1999 Jul 20; 100(3): 230–5PubMedCrossRefGoogle Scholar
  162. 162.
    Hallenbeck JM, Dutka AJ, Kochanek PM, et al. Stroke risk factors prepare rat brainstem tissues for modified local Shwartzman reaction. Stroke 1988 Jul; 19(7): 863–9PubMedCrossRefGoogle Scholar
  163. 163.
    Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998 Feb; 29(2): 415–21PubMedCrossRefGoogle Scholar
  164. 164.
    Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995 Sep; 130 (3 Pt 1): 572–9PubMedCrossRefGoogle Scholar
  165. 165.
    Kothari R, Sauerbeck L, Jauch E, et al. Patients’ awareness of stroke signs, symptoms, and risk factors. Stroke 1997; 28: 1871–5PubMedCrossRefGoogle Scholar
  166. 166.
    Pancioli AM, Broderick J, Kothari R, et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA 1998; 279: 1288–92PubMedCrossRefGoogle Scholar
  167. 167.
    Stern EB, Berman ME, Thomas JJ, et al. Community education for stroke awareness an efficacy study. Stroke 1999 Apr; 30: 720–3PubMedCrossRefGoogle Scholar
  168. 168.
    Yoon SS, Heller RF, Levi C, et al. Knowledge of stroke risk factors, warning symptoms, and treatment among an Australian urban population. Stroke 2001 Aug; 32: 1926–30CrossRefGoogle Scholar
  169. 169.
    Greenlund KJ, Giles WH, Keenan NL, et al. Physician advice, patient actions, and health-related quality of life in secondary prevention of stroke through diet and exercise. Stroke 2002 Feb; 33: 565–71PubMedCrossRefGoogle Scholar
  170. 170.
    Rodgers H, Atkinson C, Bond S, et al. Randomized controlled trial of a comprehensive stroke education program for patients and caregivers. Stroke 1999; 30: 2585–91PubMedCrossRefGoogle Scholar
  171. 171.
    Mouradian MS, Majumdar SR, Senthilselvan A, et al. How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack? Stroke 2002; 33: 1656–9PubMedCrossRefGoogle Scholar
  172. 172.
    Forster A, Smith J, Young J, et al. Information provision for stroke patients and their caregivers (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2003Google Scholar
  173. 173.
    Mueller RL, Scheidt S. History of drugs for thrombotic disease: discovery, development, and directions for the future. Circulation 1994 Jan; 89(1): 432–49PubMedCrossRefGoogle Scholar
  174. 174.
    Schror K. Antiplatelet drugs. Drugs 1995 Jul; 50(1): 7–28PubMedCrossRefGoogle Scholar
  175. 175.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994 Jan 8; 308(6921): 81–106CrossRefGoogle Scholar
  176. 176.
    Raps EC, Galetta SL. Stroke prevention therapies and management of patient subgroups. Neurology 1995 Feb; 45(2 Suppl. 1): S19–24PubMedGoogle Scholar
  177. 177.
    Leira EC, Adams Jr HP. Which patients are inappropriate for surgery and what is the “best” medical management for non-surgical patients. In: CM Loftus, TF Kresowik, editors. Carotid artery surgery. New York: Thieme, 2000: 113–20Google Scholar
  178. 178.
    Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin [letter]. J Neurol Neurosurg Psychiatry 1999 Feb; 66(2): 255PubMedCrossRefGoogle Scholar
  179. 179.
    Albers GW, Hart RG, Lutsep HL, et al. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on guidelines for the management of transient ischemic attacks, Stroke Council, American Heart Association. Stroke 1999 Nov; 30(11): 2502–11PubMedCrossRefGoogle Scholar
  180. 180.
    Farrell B, Godwin J, Richards S, et al. The United Kingdom Transient Ischemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991 Dec; 54(12): 1044–54PubMedCrossRefGoogle Scholar
  181. 181.
    A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke: the Dutch TIA Trial Study Group. N Engl J Med 1991 Oct 31; 325(18): 1261–6CrossRefGoogle Scholar
  182. 182.
    Dyken ML, Barnett HJM, Easton JD, et al. Low-dose aspirin and stroke: “it ain’t necessarily so”. Stroke 1992 Oct; 23(10): 1395–9PubMedCrossRefGoogle Scholar
  183. 183.
    Barnett HJM, Kaste M, Meldrum H, et al. Aspirin dose and stroke prevention: beautiful hypotheses slain by ugly facts. Stroke 1996 Apr; 27(4): 588–92PubMedCrossRefGoogle Scholar
  184. 184.
    Taylor DW, Barnett HJM, Haynes B, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999 Jun 26; 353(9171): 2179–84PubMedCrossRefGoogle Scholar
  185. 185.
    Goldstein LB, Bonito AJ, Matchar DB, et al. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: design, service availability, and common practices. Stroke 1995 Sep; 26(9): 1607–15PubMedCrossRefGoogle Scholar
  186. 186.
    Dyken ML. Aspirin dose in secondary prevention of stroke [letter]. Cerebrovasc Dis 1998; 8: 361–2Google Scholar
  187. 187.
    Grotta JC, Norris JW, Kamm B. Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup. Neurology 1992 Jan; 42(1): 111–5PubMedCrossRefGoogle Scholar
  188. 188.
    Rothrock JF, Hart RG. Ticlopidine hydrochloride use and threatened stroke. West J Med 1994 Jan; 160(1): 43–7PubMedGoogle Scholar
  189. 189.
    Hankey GJ. Current oral antiplatelet agents to prevent atherothrombosis. Cerebrovasc Dis 2001; 11Suppl. 2: 11–7PubMedCrossRefGoogle Scholar
  190. 190.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998 Jun 13; 351(9118): 1755–62PubMedCrossRefGoogle Scholar
  191. 191.
    Krupski WC, Weiss DG, Rapp JH, et al. Adverse effects of aspirin in the treatment of asymptomatic carotid artery stenosis: The VA Cooperative Asymptomatic Carotid Artery Stenosis Study Group. J Vasc Surg 1992 Oct; 16(4): 588–97PubMedCrossRefGoogle Scholar
  192. 192.
    Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996 Feb 26; 156(4): 409–16CrossRefGoogle Scholar
  193. 193.
    Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 1993 Mar; 35(3): 219–26PubMedCrossRefGoogle Scholar
  194. 194.
    Prichard PJ, Kitchingman GK, Daneshmend TK, et al. Human gastric mucosal bleeding by low-dose aspirin, but not warfarin. BMJ 1989 Feb 25; 298(6672): 493–6PubMedCrossRefGoogle Scholar
  195. 195.
    Hart RG, Harrison MJG. Aspirin Wars. The optimal dose of aspirin to prevent stroke. Stroke 1996 Apr; 27(4): 585–7Google Scholar
  196. 196.
    Gent M, Blakely JA, Easton D, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989 Jun 3; I(8649): 1215–20CrossRefGoogle Scholar
  197. 197.
    Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989 Aug 24; 321(8): 501–7PubMedCrossRefGoogle Scholar
  198. 198.
    Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998 Apr 1; 128(7): 541–4PubMedGoogle Scholar
  199. 199.
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov 16; 348(9038): 1329–39CrossRefGoogle Scholar
  200. 200.
    Giraud-Chaumeil B, Rascol A, David J, et al. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-aggregants plaquettaires: résults d’un essai thérapeutique controle de 3 ans [in French]. Rev Neurol (Paris) 1982; 138: 367–85Google Scholar
  201. 201.
    Bousser MG, Eschwege E, Haguenau M, et al. AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983 Jan–Feb; 14(1): 5–14PubMedCrossRefGoogle Scholar
  202. 202.
    The American-Canadian Co-Operative Study Group. Persantine Aspirin Trial in cerebral ischemia: II. End point results. Stroke 1985 May–Jun; 16(3): 406–15Google Scholar
  203. 203.
    The ESPS Group. The European Stroke Prevention Study (ESPS): principal end-points. Lancet 1987 Dec 12; II(8572): 1351–4Google Scholar
  204. 204.
    Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996 Nov; 143(1-2): 1–13PubMedCrossRefGoogle Scholar
  205. 205.
    Chong PH. Glycoprotein IIb/IIIa antagonists in the management of cardiovascular diseases. Am J Health Syst Pharm 1998 Nov 15; 55(22): 2363–86PubMedGoogle Scholar
  206. 206.
    The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000 Mar; 31(3): 601–9CrossRefGoogle Scholar
  207. 207.
    Kuwamura M, Imura Y, Moriya N, et al. Antithrombotic effects of TAK-029, a novel GPlla/lllb antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. J Pharmacol Exp Ther 1996; 227: 502–10Google Scholar
  208. 208.
    Mousa SA, Mu DX, Lucchesi BR. Prevention of carotid artery thrombosis by oral platelet GPllb/llla antagonist in dogs. Stroke 1997 Apr; 28(4): 830–5PubMedCrossRefGoogle Scholar
  209. 209.
    Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001 Nov 15; 345(20): 1444–51PubMedCrossRefGoogle Scholar
  210. 210.
    The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997 Dec; 42(6): 857–65CrossRefGoogle Scholar
  211. 211.
    Major ongoing stroke trials. Stroke 2001 Oct; 32(10): 2448–9Google Scholar
  212. 212.
    Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998 Aug 10–24; 158(15): 1641–7PubMedCrossRefGoogle Scholar
  213. 213.
    Hart RG, Bailey RD. An assessment of guidelines for prevention of ischemic stroke. Neurology 2002; 59: 977–82PubMedCrossRefGoogle Scholar
  214. 214.
    Stroke Prevention and Educational Awareness Diffusion (SPREAD) Collaboration. The Italian guidelines for stroke prevention. Neurol Sci 2000; 21: 5–12CrossRefGoogle Scholar
  215. 215.
    Albers GW, Amarenco P, Easton JD, et al. Sixth ACCP Consensus Conference on Antithrombotic Therapy: antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119 Suppl.: 300S–20SPubMedCrossRefGoogle Scholar
  216. 216.
    Albers GW, Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients? Stroke 2201; 32: 2948–9CrossRefGoogle Scholar
  217. 217.
    Alberts MJ. Clopidogrel plus aspirin for stroke prevention [letter]. Stroke 2002; 33: 2546–7PubMedCrossRefGoogle Scholar
  218. 218.
    Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998; 98: 2461–9PubMedCrossRefGoogle Scholar
  219. 219.
    Herbert JM, Dol F, Bernat A, et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80: 512–8PubMedGoogle Scholar
  220. 220.
    Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502PubMedCrossRefGoogle Scholar
  221. 221.
    Mehta S., for the CURE Investigators. Dialogue on acute coronary syndromes. Presented at the 51st Annual Scientific Sessions of the American College of Cardiology; 2001 Mar; AtlantaGoogle Scholar
  222. 222.
    Diener H-C, Bogousslavsky J, Brass LM, et al., on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–7PubMedCrossRefGoogle Scholar
  223. 223.
    Rothwell PM. Lessons from MATCH for future randomised trials in secondary prevention of stroke [comment]. Lancet 2004; 364: 305–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of Neurosurgery, c/o Editorial OfficeUniversity of Cincinnati College of MedicineCincinnatiUSA
  2. 2.The Neuroscience InstituteCincinnatiUSA
  3. 3.Mayfield ClinicCincinnatiUSA

Personalised recommendations